ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With Non-alcoholic Fatty Liver Disease (NAFLD)
Status:
Recruiting
Trial end date:
2022-02-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to assess the safety and tolerability of ALT-801 in diabetic and
non-diabetic overweight and obese subjects with non-alcoholic fatty liver disease (NAFLD).